{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:38Z","timestamp":1787037998359,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019550","name":"Scheme for Promotion of Academic and Research Collaboration","doi-asserted-by":"publisher","award":["P3345, P4008 and P 4072"],"award-info":[{"award-number":["P3345, P4008 and P 4072"]}],"id":[{"id":"10.13039\/501100019550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cefotaxime (CFT) is a broad spectrum, third-generation cephalosporin antibiotic prescribed for the treatment of severe infections, yet dosing guidelines for pediatric with renal impairment is scarce. The current study aimed to develop a physiological based pharmacokinetic (PBPK) model to characterize CFT disposition and model-based recommend dose adjustments in pediatrics with renal impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Initially, the PBPK model of CFT was developed in adults with normal renal function before being scaled to pediatrics, considering age-related physiological changes using GastroPlus\u00ae software. Renal impairment was modelled through optimization of tubular secretion and glomerular filtration parameters based on observed data for both adults and pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The model reasonably reproduced the observed pharmacokinetic profiles and showed acceptable agreement with the data (fold error ranges 0.84\u20131.37) or with renal impairment (fold error ranges 0.87\u20131.12). When compared to children with normal renal function, the predicted AUC0\u2212\u221e in children with renal impairment increased to 1.22- and 1.89-fold for moderate and severe renal impairment, respectively. Model-informed dose recommendations were 60% and 48% of the standard pediatric dose for moderate and severe renal impairment, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This PBPK framework supports rational, model-informed dosing of CFT in pediatric patients with varying renal impairment and supports dose recommendation development for high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04121-8","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:40:21Z","timestamp":1783651221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based pharmacokinetic modeling of cefotaxime to inform pediatric dosing in renal impairment"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-8134","authenticated-orcid":false,"given":"Najia","family":"Rahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0516-4966","authenticated-orcid":false,"given":"Muhammad","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-7558","authenticated-orcid":false,"given":"Muhammad","family":"Wahajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"9","key":"4121_CR1","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/antibiotics13090862","volume":"13","author":"K Abduljalil","year":"2024","unstructured":"Abduljalil K, Gardner I, Jamei M (2024) Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance. Antibiotics 13(9):862","journal-title":"Antibiotics"},{"issue":"9","key":"4121_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","volume":"98","author":"BJ Anderson","year":"2013","unstructured":"Anderson BJ, Holford NH (2013) Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 98(9):737\u2013744","journal-title":"Arch Dis Child"},{"issue":"4","key":"4121_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","volume":"13","author":"LZ Benet","year":"2011","unstructured":"Benet LZ, Broccatelli F, Oprea TI (2011) BDDCS applied to over 900 drugs. Aaps j 13(4):519\u2013547. https:\/\/doi.org\/10.1208\/s12248-011-9290-9","journal-title":"Aaps j"},{"issue":"1","key":"4121_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0002-9343(60)90225-4","volume":"28","author":"NS Bricker","year":"1960","unstructured":"Bricker NS, Morrin PA, Kime SW Jr (1960) The pathologic physiology of chronic Bright\u2019s disease: an exposition of the intact nephron hypothesis. Am J Med 28(1):77\u201398","journal-title":"Am J Med"},{"issue":"2","key":"4121_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2165\/00003088-197601020-00004","volume":"1","author":"L Dettli","year":"1976","unstructured":"Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1(2):126\u2013134","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4121_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/antibiotics13040313","volume":"13","author":"T Dillies","year":"2024","unstructured":"Dillies T, Perinel-Ragey S, Correia P, Morel J, Thiery G, Launay M (2024) Dosing Regimen for Cefotaxime Should Be Adapted to the Stage of Renal Dysfunction in Critically Ill Adult Patients\u2014A Retrospective Study. Antibiotics 13(4):313","journal-title":"Antibiotics"},{"key":"4121_CR7","unstructured":"Drug. Com from https:\/\/www.drugs.com\/mtm\/cefotaxime.html.\u00a0 Accessed 10 Aug 2025"},{"issue":"7","key":"4121_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40262-022-01121-6","volume":"61","author":"S Dubinsky","year":"2022","unstructured":"Dubinsky S, Malik P, Hajducek DM, Edginton A (2022) Determining the effects of chronic kidney disease on organic anion Transporter1\/3 activity through physiologically based pharmacokinetic modeling. Clin Pharmacokinet 61(7):997\u20131012","journal-title":"Clin Pharmacokinet"},{"issue":"supplA","key":"4121_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jac\/6.suppl_A.83","volume":"6","author":"F Esmieu","year":"1980","unstructured":"Esmieu F, Guibert J, Rosenkilde H, Ho I, Go AL (1980) Pharmacokinetics of cefotaxime in normal human volunteers. J Antimicrob Chemother 6(supplA):83\u201392","journal-title":"J Antimicrob Chemother"},{"key":"4121_CR10","unstructured":"FDA (2015) CLAFORAN\u00ae"},{"key":"4121_CR11","unstructured":"Sterile (cefotaxime for injection, USP). Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/050547s071,050596s042lbl.pdf#:~:text=Anaerobic\/bacteria\/(agar\/method)\/E2\/89\/A41\/202\/E2\/89\/A54,only\/penicillin\/and\/either\/cefoxitin\/or\/oxacillin"},{"issue":"8","key":"4121_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11095-022-03250-w","volume":"39","author":"S Frechen","year":"2022","unstructured":"Frechen S, Rostami-Hodjegan A (2022) Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom? Pharm Res 39(8):1733\u20131748. https:\/\/doi.org\/10.1007\/s11095-022-03250-w","journal-title":"Pharm Res"},{"issue":"1","key":"4121_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40272-022-00535-w","volume":"25","author":"JJ Freriksen","year":"2023","unstructured":"Freriksen JJ, van der Heijden JE, de Hoop-Sommen MA, Greupink R, de Wildt SN (2023) Physiologically based pharmacokinetic (PBPK) model-informed dosing guidelines for pediatric clinical care: a pragmatic approach for a special population. Pediatr Drugs 25(1):5\u201311","journal-title":"Pediatr Drugs"},{"issue":"5","key":"4121_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1128\/AAC.16.5.592","volume":"16","author":"KP Fu","year":"1979","unstructured":"Fu KP, Aswapokee P, Ho I, Matthijssen C, Neu H (1979) Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 16(5):592\u2013597","journal-title":"Antimicrob Agents Chemother"},{"issue":"supplA","key":"4121_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jac\/6.suppl_A.219","volume":"6","author":"W Gl\u00f6ckner","year":"1980","unstructured":"Gl\u00f6ckner W, H\u00f6ffler U, Kindler J, Peters G, Sieberth H (1980) Elimination kinetics of cefotaxime in patients with renal insufficiency requiring dialysis. J Antimicrob Chemother 6(supplA):219\u2013223","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4121_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, Roger C (2019) Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR). Crit Care 23(1):104","journal-title":"Crit Care"},{"issue":"supplB","key":"4121_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jac\/8.suppl_B.263","volume":"8","author":"S Harding","year":"1981","unstructured":"Harding S, Monro A, Thornton JE, Ayrton J, Hogg M (1981) The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother 8(supplB):263\u2013272","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"4121_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF00637745","volume":"36","author":"L Hary","year":"1989","unstructured":"Hary L, Andrejak M, Leleu S, Orfila J, Capron J (1989) The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol 36(6):613\u2013616","journal-title":"Eur J Clin Pharmacol"},{"issue":"4\u20135","key":"4121_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1159\/000513698","volume":"50","author":"TA Ikizler","year":"2021","unstructured":"Ikizler TA, Cuppari L (2021) The 2020 updated KDOQI clinical practice guidelines for nutrition in chronic kidney disease. Blood Purif 50(4\u20135):667\u2013671","journal-title":"Blood Purif"},{"key":"4121_CR20","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/jcph.1869","volume":"61","author":"I Ince","year":"2021","unstructured":"Ince I, Dallmann A, Frechen S, Coboeken K, Niederalt C, Wendl T, Burghaus R (2021) Predictive performance of physiology-based pharmacokinetic dose estimates for pediatric trials: evaluation with 10 Bayer small\u2010molecule compounds in children. J Clin Pharmacol 61:S70\u2013S82","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4121_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF01059394","volume":"13","author":"R Ings","year":"1985","unstructured":"Ings R, Reeves D, White L, Bax R, Bywater M, Holt H (1985) The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. J Pharmacokinet Biopharm 13(2):121\u2013142","journal-title":"J Pharmacokinet Biopharm"},{"issue":"Supplement2","key":"4121_CR22","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1093\/clinids\/4.Supplement_2.S379","volume":"4","author":"RM Ings","year":"1982","unstructured":"Ings RM, Fillastre J-P, Godin M, Leroy A, Humbert G (1982) The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis 4(Supplement2):S379\u2013S391","journal-title":"Rev Infect Dis"},{"issue":"4","key":"4121_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.20.4.487","volume":"20","author":"DA Kafetzis","year":"1981","unstructured":"Kafetzis DA, Brater DC, Kanarios J, Sinaniotis CA, Papadatos CJ (1981) Clinical pharmacology of cefotaxime in pediatric patients. Antimicrob Agents Chemother 20(4):487\u2013490","journal-title":"Antimicrob Agents Chemother"},{"key":"4121_CR24","doi-asserted-by":"crossref","unstructured":"Ke CJ, Liu ST, Qian YD, You X, Lin RF, Lin CH.,., Lin WW (2025) Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages. Br J Clin Pharmacol","DOI":"10.1002\/bcp.70016"},{"issue":"3","key":"4121_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1128\/AAC.23.3.429","volume":"23","author":"B Kemmerich","year":"1983","unstructured":"Kemmerich B, Lode H, Belmega G, Jendroschek T, Borner K, Koeppe P (1983) Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 23(3):429\u2013434","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4121_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/j.1875-9114.1982.tb03185.x","volume":"2","author":"JL LeFrock","year":"1982","unstructured":"LeFrock JL, Prince RA, Left RD (1982) Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime. Pharmacotherapy: J Hum Pharmacol Drug Therapy 2(4):174\u2013184","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"8","key":"4121_CR27","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.xphs.2024.03.002","volume":"113","author":"Q Li","year":"2024","unstructured":"Li Q, Guan Y, Xia C, Wu L, Zhang H, Wang Y (2024) Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates. J Pharm Sci 113(8):2605\u20132615","journal-title":"J Pharm Sci"},{"issue":"2","key":"4121_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.2452","volume":"112","author":"Q Liu","year":"2022","unstructured":"Liu Q, Schwartz JB, Slattum PW, Lau SJ, Guinn D, Madabushi R, Cho C (2022) Roadmap to 2030 for drug evaluation in older adults. Clin Pharmacol Ther 112(2):210\u2013223","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4121_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acs.molpharmaceut.0c00903","volume":"18","author":"I Loisios-Konstantinidis","year":"2020","unstructured":"Loisios-Konstantinidis I, Dressman J (2020) Physiologically based pharmacokinetic\/pharmacodynamic modeling to support waivers of in vivo clinical studies: current status, challenges, and opportunities. Mol Pharm 18(1):1\u201317","journal-title":"Mol Pharm"},{"key":"4121_CR30","doi-asserted-by":"crossref","unstructured":"Lou J-Q, Huo B-N, Yang Y, Wang S-F, Zhang L-D, Jia Y-T, Song L (2025) Physiologically based pharmacokinetic modeling and dose optimization of linezolid in pediatric patients with renal impairment. Drug Des Devel Ther 9: 8427\u20138440","DOI":"10.2147\/DDDT.S525400"},{"issue":"5","key":"4121_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/AAC.20.5.567","volume":"20","author":"R L\u00fcthy","year":"1981","unstructured":"L\u00fcthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W (1981) Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother 20(5):567\u2013575","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4121_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","volume":"53","author":"I Mahmood","year":"2014","unstructured":"Mahmood I (2014) Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet 53(4):327\u2013346","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4121_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/clpt.1985.130","volume":"38","author":"GR Matzke","year":"1985","unstructured":"Matzke GR, Abraham PA, Halstenson CE, Keane WF (1985) Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther 38(1):31\u201336","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"4121_CR34","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1128\/AAC.35.9.1879","volume":"35","author":"C Paap","year":"1991","unstructured":"Paap C, Nahata M, Mentser M, Mahan J, Puri S, Hubbard J (1991) Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction. Antimicrob Agents Chemother 35(9):1879\u20131883","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4121_CR35","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/ph17070924","volume":"17","author":"M Pasha","year":"2024","unstructured":"Pasha M, Zamir A, Rasool MF, Saeed H, Ahmad T, Alqahtani NS, Alqahtani F (2024) A comprehensive physiologically based Pharmacokinetic model for predicting vildagliptin pharmacokinetics: insights into dosing in renal impairment. Pharmaceuticals 17(7):924","journal-title":"Pharmaceuticals"},{"issue":"1","key":"4121_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1208\/s12249-024-03026-y","volume":"26","author":"N Rahim","year":"2025","unstructured":"Rahim N, Sarfraz M, Bello A, Naqvi SBS (2025) Dosage Optimization Using Physiologically Based Pharmacokinetic Modeling for Pediatric Patients with Renal Impairment: A Case Study of Meropenem. AAPS PharmSciTech 26(1):38","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"4121_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","volume":"116","author":"K Rowland Yeo","year":"2024","unstructured":"Rowland Yeo K, Gil Berglund E, Chen Y (2024) Dose optimization informed by PBPK modeling: state-of\u2010the art and future. Clin Pharmacol Ther 116(3):563\u2013576","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4121_CR38","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s11064-021-03472-1","volume":"47","author":"Y Shan","year":"2022","unstructured":"Shan Y, Cen Y, Zhang Y, Tan R, Zhao J, Nie Z, Yu S (2022) Effect of P-glycoprotein Inhibition on the Penetration of Ceftriaxone Across the Blood\u2013Brain Barrier. Neurochem Res 47(3):634\u2013643. https:\/\/doi.org\/10.1007\/s11064-021-03472-1","journal-title":"Neurochem Res"},{"issue":"29","key":"4121_CR39","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.1007\/s00216-016-9929-6","volume":"408","author":"M Szultka-Mlynska","year":"2016","unstructured":"Szultka-Mlynska M, Buszewski B (2016) Study of in-vitro metabolism of selected antibiotic drugs in human liver microsomes by liquid chromatography coupled with tandem mass spectrometry. Anal Bioanal Chem 408(29):8273\u20138287. https:\/\/doi.org\/10.1007\/s00216-016-9929-6","journal-title":"Anal Bioanal Chem"},{"issue":"4","key":"4121_CR40","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2165\/00003495-199040040-00008","volume":"40","author":"PA Todd","year":"1990","unstructured":"Todd PA, Brogden RN (1990) Cefotaxime: an update of its pharmacology and therapeutic use. Drugs 40(4):608\u2013651","journal-title":"Drugs"},{"issue":"6","key":"4121_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/AAC.28.6.791","volume":"28","author":"JM Trang","year":"1985","unstructured":"Trang JM, Jacobs R, Kearns G, Brown A, Wells T, Underwood F, Kluza R (1985) Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrob Agents Chemother 28(6):791\u2013795","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4121_CR42","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1128\/AAC.35.10.2057","volume":"35","author":"F Vallee","year":"1991","unstructured":"Vallee F, LeBel M (1991) Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime. Antimicrob Agents Chemother 35(10):2057\u20132064","journal-title":"Antimicrob Agents Chemother"},{"key":"4121_CR43","doi-asserted-by":"crossref","unstructured":"Varnekar S, Sohal M, Tikale N, Reddy S R, Bose A, Pawar S, Kurkute P (2025) In: Gudhanti SNKR, Alavala RR (eds) Physiologically based pharmacokinetic (PBPK) modeling and pharmacokinetic pharmacodynamic (PKPD) modelling. In Applications of computational tools in drug design and development, Springer Nature Singapore, (pp 475-515)","DOI":"10.1007\/978-981-96-4154-3_14"},{"key":"4121_CR44","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1002\/jcph.1841","volume":"61","author":"AA Vinks","year":"2021","unstructured":"Vinks AA, Barrett JS (2021) Model-informed pediatric drug development: application of pharmacometrics to define the right dose for children. J Clin Pharmacol 61:S52\u2013S59","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4121_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/aac.40.2.362","volume":"40","author":"MA Visalli","year":"1996","unstructured":"Visalli MA, Jacobs MR, Appelbaum PC (1996) MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 40(2):362\u2013366. https:\/\/doi.org\/10.1128\/aac.40.2.362","journal-title":"Antimicrob Agents Chemother"},{"key":"4121_CR46","unstructured":"WHO (2010) Characterization and application of physiologically based pharmacokinetic models in risk assessment. https:\/\/www.who.int\/publications\/i\/item\/9789241500906"},{"issue":"Suppl 1","key":"4121_CR47","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1007\/BF01644237","volume":"13","author":"R Wise","year":"1985","unstructured":"Wise R, Wright N (1985) The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction. Infection 13(Suppl 1):S145\u2013S150","journal-title":"Infection"},{"issue":"4","key":"4121_CR48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1128\/AAC.19.4.526","volume":"19","author":"R Wise","year":"1981","unstructured":"Wise R, Wright N, Wills P (1981) Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrob Agents Chemother 19(4):526\u2013531","journal-title":"Antimicrob Agents Chemother"},{"key":"4121_CR49","doi-asserted-by":"publisher","first-page":"838599","DOI":"10.3389\/fphar.2022.838599","volume":"13","author":"L Ye","year":"2022","unstructured":"Ye L, You X, Zhou J, Wu C, Ke M, Wu W, Lin C (2022) Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment. Front Pharmacol 13:838599","journal-title":"Front Pharmacol"},{"issue":"9","key":"4121_CR50","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1002\/jps.23581","volume":"102","author":"SW Yee","year":"2013","unstructured":"Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Tahara H (2013) Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci 102(9):3451\u20133457","journal-title":"J Pharm Sci"},{"issue":"2","key":"4121_CR51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40262-024-01469-x","volume":"64","author":"F Zbib","year":"2025","unstructured":"Zbib F, Deschamps A, Velly L, Blin O, Guilhaumou R, Gattacceca F (2025) Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function. Clin Pharmacokinet 64(2):257\u2013273","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04121-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:35Z","timestamp":1787036135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04121-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"196"}}